Journals / Meme Sağlığı Dergisi / 2006 / Cilt: 2 - Sayı: 1

Does peritumoral LYVE-1 immunoreactivity predict the sentinel lymph node metastasis?

Bekçi lenf düğümü metastazlarını, peritümöral LYVE-1 immunreaktivite öngörür mü?

Pages
23–25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On conlusion, as a novel lymphangiogenesis marker LYVE-1, has limited predictive values for the evaluation of sentinel lymph node metastasis in patients with early breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:LYVE-1 is a -recently identified- selective lymphatic endothelial surface receptor which plays mainly role on transportation of hyaluronan from extracellular matrix to the regional lymph nodes.
📊
Key Findings & Data:In a few cancer studies, relationships between LYVE-1/Hyaluronan and lymphatic invasion and metastasis has been shown.
💡
Conclusion & Impact:On conlusion, as a novel lymphangiogenesis marker LYVE-1, has limited predictive values for the evaluation of sentinel lymph node metastasis in patients with early breast cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lenfatik metastaz · Testlerin kestirim değeri · Neoplazm metastazı

Abstract

LYVE-1 is a -recently identified- selective lymphatic endothelial surface receptor which plays mainly role on transportation of hyaluronan from extracellular matrix to the regional lymph nodes. In a few cancer studies, relationships between LYVE-1/Hyaluronan and lymphatic invasion and metastasis has been shown. However, predictive values of peritumoral or intratumoral LYVE-1 positivity for the assesment of regional lymphatic invasion is unknown. In the present study, we aimed to investigate whether the peri/intratumoral LYVE-1 immunoreactivity related to sentinel lymph node status in 25 breast-cancer-patients. Sentinel lymph node (SLN) biopsy was performed by using combined technique with vital blue dye and hand-held gamma probe dedection in patients with early breast cancer. Lymphoscintigraphy was performed in all patients. Metastases to sentinel lymph nodes was evaluated both Hematoxylene/Eosine (HE) and immunohistochemical (IHC) staining. Serial sections which contain both invasive tumor and peri-tumoral area from the original block were cut (4 um) and stained with HE and LYVE-1. "LYVE-1 antibody-lymphatic vessel marker" was used for IHC analysis. The sensitivity and specifity of the method were established as 67% and 71% respectively. The LYVE-1 positivity was mostly peritumoral (85 %) Negative and positive predictive values of LYVE-1 immunostaining were 77% and 60% respectively. On conlusion, as a novel lymphangiogenesis marker LYVE-1, has limited predictive values for the evaluation of sentinel lymph node metastasis in patients with early breast cancer.

Özet

LYVE-1 lenfatik endotele özgü, yeni keşfedilmiş bir hücre yüzeyi reseptörüdür. Hyaluronan'ın extrasellüler matrixten lenf düğümüne aktarılma işlevinde rol alır. Sınırlı sayıda çalışma lenfatik invazyon ve metastazda LYVE-1/Hyaluronan ilişkisinin rol oynadığını göstermiştir. Malign meme tümörlerinde peritümöral ve intratümöral LYVE-1 pozitifliğinin, bölgesel lenfatik metastaz varlığını ne derecede öngörebileceği iyi bilinmeyen bir konudur. Bu çalışmada meme kanserli olup, bekçi lenf düğümü biyopsisi yapılan 25 olguda immunohistokimyasal (İHK) olarak LYVE-1 boyanmasının bölgesel lenf düğümü yayılım varlığını ne derecede gösterdiği incelendi. Bekçi lenf düğümü biyopsisi T1 ve T2 invaziv meme kanseri olgularında gamma dedeksiyon ve vital boyanma yöntemlerinin birlikte kullanımı ile belirlendi. Tüm olgularda lenfosintigrafi elde olundu. Bekçi lenf düğümlerindeki yayılım, Hematoksilen-Eosin (HE) ve standart İHK boyaması ile belirlendi. Analiz için, tümör ve çevresini içeren HE boyalı kesitler seçildi. Bunların parafin bloklarından polilizinli lamlara 4 mikronluk kesitler alındı. LYVE-1, "LYVE1 antibody - Lymphatic Vessel Marker" ı kullanılarak Immunohistokimyasal yöntemle incelendi. Yöntemin özgüllüğü % 71, duyarlığı %67, pozitif öngörüsü % 60, negatif öngörüsü % 77 olarak belirlendi. İmmunreaktivitenin % 85 i peritümöral, % 15 i intratümöral bölgede belirlendi. Sonuç olarak, lenfanjiogenetik bir belirteç olan LYVE-1'in , meme kanserli olgularda bölgesel lenfatik metastazın belirlenmesinde sınırlı bir etkinliğe sahip olduğu düşünüldü.

🔖

Cite This Article

KOÇDOR, H., KOÇDOR, M. A., CANDA, T., BEKİŞ, R., SEVİNÇ, A., SAYDAM, S., HARMANCIOĞLU, Ö. (2006). Does peritumoral LYVE-1 immunoreactivity predict the sentinel lymph node metastasis?. Meme Sağlığı Dergisi, Cilt: 2 - Sayı: 1, 23–25. https://ajindex.com/articles/278296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24740 breast cancer cases. Cancer 1989; 63:181- 187
  2. Kelley MC, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Am J Surg, 2004; 188:49-61
  3. Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS, 2004;112:526-538
  4. Banerji S, Ni J, Wang SX et al. LYVE-1, a new homologue od the CD44 glycoprotein, is alymph specific receptor for hyaluronan. J Cell Biol 19- 99;144:789-801
  5. Bono P, Wasenius V-M, Heikkila P, Lundin J, Jackson D, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Research, 2004; 10: 7144-7149
  6. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. LYVE�1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol. 2005 Feb; 58(2):202.-206
  7. Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol, 2005 (Baskıda)
  8. Cory CSM, Leek RD, Robson AM et.al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol, 2003;200:195-206
  9. Viguel MM, Bos R, van der Groep et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol, 2004; 57:746-751
  10. Trojan L, Michel MS, Rensch F, et al. Lymph and blood vessel architecture in benign and malignant prostatic tissue: Lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol, 2004;172:103-107.